Ectopic expression of ceramide synthase 2 in neurons suppresses neurodegeneration induced by ceramide synthase 1 deficiency

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 21, 2016, Pages 5928-5933

  Spassieva, Stefka D ^a   Ji, Xiaojie ^b,c   Liu, Ye ^b   Gable, Kenneth ^d   Bielawski, Jacek ^e   Dunn, Teresa M ^d   Bieberich, Erhard ^f   Zhao, Lihong ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b JACKSON LABORATORY   (United States)

^c UNIVERSITY OF MAINE   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Ceramide; Ceramide synthase; Long chain base; Neurodegeneration; Sphingolipid

Indexed keywords

CERAMIDE; CERAMIDE SYNTHASE 1; CERAMIDE SYNTHASE 2; SPHINGOLIPID; SYNTHETASE; UNCLASSIFIED DRUG; CERS1 PROTEIN, MOUSE; CERS2 PROTEIN, MOUSE; MEMBRANE PROTEIN; SPHINGOSINE ACYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ECTOPIC EXPRESSION; ENZYME DEFICIENCY; IN VITRO STUDY; MOUSE; MOUSE MUTANT; NERVE DEGENERATION; NEURITE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BIOSYNTHESIS; BRAIN; DEFICIENCY; DEGENERATIVE DISEASE; DISEASE MODEL; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY;

ANIMALS; BRAIN; CELL SURVIVAL; CERAMIDES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; MEMBRANE PROTEINS; MICE; MICE, MUTANT STRAINS; NEURITES; NEURODEGENERATIVE DISEASES; SPHINGOLIPIDS; SPHINGOSINE N-ACYLTRANSFERASE;

EID: 84969785118     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1522071113     Document Type: Article

References (40)

1. Bartke N, Hannun YA (2009) Bioactive sphingolipids: Metabolism and function. J Lipid Res 50(Suppl):S91-S96.
2. Merrill AH, Jr (2011) Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-6422.
3. Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol 9(2):139-150.
4. Gable K, et al. (2010) A disease-causing mutation in the active site of serine palmitoyltransferase causes catalytic promiscuity. J Biol Chem 285(30):22846-22852.
5. Penno A, et al. (2010) Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J Biol Chem 285(15):11178-11187.
6. Kramer R, et al. (2015) Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. FASEB J 29(11):4461-4472.
7. Kanno T, Nishizaki T (2011) Sphingosine induces apoptosis in hippocampal neurons and astrocytes by activating caspase-3/-9 via a mitochondrial pathway linked to SDK/ 14-3-3 protein/Bax/cytochrome c. J Cell Physiol 226(9):2329-2337.
8. Moore AN, Kampfl AW, Zhao X, Hayes RL, Dash PK (1999) Sphingosine-1-phosphate induces apoptosis of cultured hippocampal neurons that requires protein phosphatases and activator protein-1 complexes. Neuroscience 94(2):405-415.
9. Marasas WF, et al. (2004) Fumonisins disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: A potential risk factor for human neural tube defects among populations consuming fumonisincontaminated maize. J Nutr 134(4):711-716.
10. Koybasi S, et al. (2004) Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem 279(43):44311-44319.
11. Senkal CE, Ponnusamy S, Bielawski J, Hannun YA, Ogretmen B (2010) Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J 24(1):296-308.
12. Senkal CE, et al. (2007) Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 6(2):712-722.
13. Ben-David O, Futerman AH (2010) The role of the ceramide acyl chain length in neurodegeneration: Involvement of ceramide synthases. Neuromolecular Med 12(4): 341-350.
14. Stiban J, Tidhar R, Futerman AH (2010) Ceramide synthases: Roles in cell physiology and signaling. Adv Exp Med Biol 688:60-71.
15. Levy M, Futerman AH (2010) Mammalian ceramide synthases. IUBMB Life 62(5): 347-356.
16. Laviad EL, et al. (2008) Characterization of ceramide synthase 2: Tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 283(9): 5677-5684.
17. Becker I, Wang-Eckhardt L, Yaghootfam A, Gieselmann V, Eckhardt M (2008) Differential expression of (dihydro)ceramide synthases in mouse brain: Oligodendrocyte-specific expression of CerS2/Lass2. Histochem Cell Biol 129(2):233-241.
18. Jazwinski SM, et al.; Georgia Centenarian Study and the Louisiana Healthy Aging Study (2010) HRAS1 and LASS1 with APOE are associated with human longevity and healthy aging. Aging Cell 9(5):698-708.
19. Vanni N, et al. (2014) Impairment of ceramide synthesis causes a novel progressive myoclonus epilepsy. Ann Neurol 76(2):206-212.
20. Zhao L, et al. (2011) A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation. PLoS Genet 7(5):e1002063.
21. Ginkel C, et al. (2012) Ablation of neuronal ceramide synthase 1 in mice decreases ganglioside levels and expression of myelin-associated glycoprotein in oligodendrocytes. JBiolChem287(50):41888-41902.
22. Mucke L, et al. (1994) Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res 666(2):151-167.
23. Mao C, Xu R, Bielawska A, Obeid LM (2000) Cloning of an alkaline ceramidase from Saccharomyces cerevisiae. An enzyme with reverse (CoA-independent) ceramide synthase activity. J Biol Chem 275(10):6876-6884.
24. Spassieva SD, Mullen TD, Townsend DM, Obeid LM (2009) Disruption of ceramide synthesis by CerS2 down-regulation leads to autophagy and the unfolded protein response. Biochem J 424(2):273-283.
25. Baird RD, et al. (2009) Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol Cancer Ther 8(6):1430-1437.
26. Massard C, et al. (2012) Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. Invest New Drugs 30(6):2318-2326.
27. Schöffski P, et al. (2011) Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: Results of a phase I dose-escalating study in patients with advanced solid malignancies. Cancer Chemother Pharmacol 68(6):1397-1403.
28. Scandroglio F, et al. (2008) Lipid content of brain, brain membrane lipid domains, and neurons from acid sphingomyelinase deficient mice. J Neurochem 107(2):329-338.
29. Yamashita T, et al. (2005) Conditional LoxP-flanked glucosylceramide synthase allele controlling glycosphingolipid synthesis. Genesis 43(4):175-180.
30. Takamiya K, et al. (1996) Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci USA 93(20):10662-10667.
31. Sheikh KA, et al. (1999) Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci USA 96(13):7532-7537.
32. Yamashita T, et al. (2005) Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc Natl Acad Sci USA 102(8):2725-2730.
33. Wang K, et al. (2015) Alkaline ceramidase 3 deficiency results in Purkinje cell degeneration and cerebellar ataxia due to dyshomeostasis of sphingolipids in the brain. PLoS Genet 11(10):e1005591.
34. Miyata M, Miyata H, Mikoshiba K, Ohama E (1999) Development of Purkinje cells in humans: An immunohistochemical study using a monoclonal antibody against the inositol 1,4,5-triphosphate type 1 receptor (IP3R1). Acta Neuropathol 98(3):226-232.
35. Bhat RV, et al. (1996) Expression of the APC tumor suppressor protein in oligodendroglia. Glia 17(2):169-174.
36. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402-408.
37. Harmon JM, et al. (2013) Topological and functional characterization of the ssSPTs, small activating subunits of serine palmitoyltransferase. J Biol Chem 288(14): 10144-10153.
38. Zhao L, et al. (2015) Elevation of 20-carbon long chain bases due to a mutation in serine palmitoyltransferase small subunit b results in neurodegeneration. Proc Natl Acad Sci USA 112(42):12962-12967.
39. Seibenhener ML, Wooten MW (2012) Isolation and culture of hippocampal neurons from prenatal mice. J Vis Exp (65):e3634.
40. Bieberich E, MacKinnon S, Silva J, Yu RK (2001) Regulation of apoptosis during neuronal differentiation by ceramide and b-series complex gangliosides. J Biol Chem 276(48):44396-44404.